sentiment us larg cap remain poor macro
company-specif overhang remain focu investor year-to-d
ibb xbi under-perform
ytd view investor remain concern drug price growth
recent phase failur recent decis trump administr
keep statu quo medicar part rebat fulli resolv
concern drug price reform focu shift may shift
reimburs part also key legal overhang particularli
on-going lawsuit novartis/sandoz enbrel ipr
file regard tecfidera ip district court expect day
compani manag guid rule altern
could see settlement compani
backdrop drug price legal overhang regard
ip see continu neg sentiment sector still recent
gilead/ galapago deal allergan deal transact continu
could help revers sentiment trend remaind
overal think result across name fine result
typic better although highlight area name could
stronger vertex neurocrin weaker regeneron
discuss view sector go earn host
call global biopharma colleagu today monday juli
increas would like improv sentiment
reflect larg cap pharma deal year gilead galapago
deal help recharg interest investor may sit round
gilead believ compani becom interest stori
overal continu posit sector look evid
increas focu especi gilead
vertex neurocrin well pois ahead quarter vertex
project higher ep compar factset consensu
averag revenu cs vs continu believ
guidanc conserv beatabl neurocrin could beat
ingrezza revenu given downbeat sentiment
regeneron could face challeng quarter project
lower revenu compar consensu ms
sma headwind high-impact catalyst buy-back could help
ep benefit like short-liv beyond could
challeng achiev meaning growth without larg
scale deal look regeneron continu believ current
consensu expect sanofi partnership high may
contribut anoth revenu miss
chang tp regeneron well updat ep
estim gilead regeneron
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
revenu ep continu wait transform
 project lower revenu compar consensu
factset view headwind ms sma franchis could drive
higher expect eros less focu near-term ms
franchis could face signific competit entri oral gener
improv traction roch ocrevu believ vumer aka
tecfidera like revers trend long-term sma franchis
recent fda approv novarti zolgensma gene therapi take share
new incid type patient view modestli consensu
expect see signific impact later zolgensma launch
although commentari novarti call seem optimist drug
launch look pipelin see modest opportun al stroke
painal unlik drive signific revenu upsid believ
revers current cours compani need undergo
transform later stage asset analysi suffici
capac deal achiev someth meaning
balanc requir strateg shift manag away
share buyback quarter ep result could benefit somewhat
decreas share count acceler buy-back think
would short-liv unlik driver perform
dcf-base tp unchang minor model adjust
reiter under-perform rate
focu point call expect commentari outlin greater detail
compani capit alloc strategi continu buy-back commit
 expect compani discuss dynam ms sma
market also look updat eisai partnership alzheim
diseas ad compani commit revisit relationship post
aducanumab failur overal see high impact catalyst
valuat metric
number share
price month
 close
charl martineau pm univers toronto figur biogen quarterli annual ep usd
profit tax
cog revenu
 revenu
sg revenu
model adjust reduc rituxan revenu
reflect recent eros trend maintain full-year estim adjust
cog downward inventori relat gross margin compress expect
continu also includ addit share buyback per manag
commentari priorit repurchas forecast ep
ep ep
profit tax
cog revenu
 revenu
sg revenu
gener in-lin revenu jakafi growth price stock
continu believ long-term upsid jakafi well appreci cs
vs factset consensu view jakafi best-in-class
treatment like remain market leader myelofibrosi
polycythemia vera jakafi expect line consensu
figur ahead typic record lower sale
season factor anticip major surpris iclusig
jakavi ex-u jakafi olumi revenu in-lin consensu
concern relianc jakafi revenu like
progress made pipelin asset capmatinib topic ruxolitinib also saw
expand indic jakafi graft-versus-host diseas steroid-
refractori acut patient individu level pipelin asset
unlik significantli take pressur jakafi howev cumul valu
pipelin asset
diversif success show us might found path
forward epacadostat failur build diversifi pipelin howev
await greater clinic progress ascrib valu asset
reiter tp neutral rate
focu point call beyond jakafi revenu look updat data
cholangiocarcinoma along
regulatori submiss fda ema also await updat data
releas time itacitinib may provid detail
commerci plan topic ruxolitinib whether out-licens
asset spin-off/ sale intern commerci
valuat metric
number share
pemigatinib
price month
 close
profit loss tax
cog revenu
 revenu
sg revenu
consensu continu believ sanofi collabor
estim high expect continu progress launch
dupix ad asthma recent crswnp nasal polyp howev see
reason near-term revenu exceed consensu estim partial due
robust track dupix prescript trend analyst investor
also cautiou asthma launch given competit natur
biolog market indic continu believ revenu miss
earn partli due mis-model collabor revenu
contribut outsiz estim could happen
forecast below-consensu sanofi collabor revenu vs
consensu see eylea sale reach peak potenti
competit novarti brolucizumab expect earli later year
modestli consensu eylea estim cs vs con
overal like compani innov think expect
key revenu gener line-item high
minor model adjust lower tp
reiter neutral rate
focu point call may see increment updat oncolog
pipelin asset pozelimab pnh nhl given
posit data eha could also see initi data alnylam
partnership nash focus therapeut bluebird car-t/cell-therapi
regeneron may provid commentari dupix asthma launch
thought potenti competit novarti brolucizumab eylea
development regulatori market
valuat metric
number share
tp rate
intellectu properti clinic
price month
 close
inc engag discoveri
invent develop manufactur commerci
medicin treatment seriou diseas
price jul rate neutral target price analyst evan seigerman
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky scenario assum better expect
sale dupix praluent kevzara libtayo eylea
grey sky scenario assum lower forecast
competit across core busi eylea dupix praluent
libtayo kevzara
figur regeneron quarterli annual ep usd
profit loss tax
cog revenu
 revenu
sg revenu
model updat made minor adjust eylea estim
reflect recent commerci trend commentari full-year sale
estim remain unchang remov forecast
revenu reflect remov model mileston payment teva
see materi quarter await addit updat compani ad
back model adjust collabor cost upward previous
reflect addit cost associ dupix commerci progress
figur forecast ep ep
ep
profit loss tax
cog revenu
 revenu
sg revenu
slightli ep remain cautious optimist new ceo
strategi gilead project non-gaap ep vs con
view hiv franchis like achiev consensu estim
market well-understood though long-term expect hiv franchis
declin howev like recent execut oday strategi
cours saw overhang filgotinib remov move drug forward
recent galapago deal step right direct like
option expand pipelin osteoarthr idiopath pulmonari
fibrosi would prefer outright acquisit gain full
econom right galapago asset final gilead chief scientif offic
john mchutchison left compani last week addit departur
greg alton kati watson also saw new ceo appoint kite
christi shaw lilli biomedicin event increas convict
oday continu execut improv strategi compani yet
need see larger scale continu execut around long-
term growth trajectori busi improv minor model
adjust dcf-base tp unchang reiter
focu point call expect consider discuss outlin
oday strateg vision potenti hint greater clinic area
interest could also get commentari on-going commerci
effort biktarvi could get glimps new kite ceo christi shaw plan
kite believ effort acceler sale yescarta would
seen positivea like prioriti new ceo given oday tenur
roch think formal separ kite distinct busi unit could
help foster innov akin roch handl genentech
valuat metric
number share
price month
 close
charl martineau pm univers toronto figur gilead quarterli annual ep usd
profit loss tax
cog revenu
 revenu
sg revenu
model updat expect us filgotinib launch ra contribut
revenu ep reduc ep
estim reflect paid galapago ad
risk adjust us sale ipf launch unadjust peak sale
po oa launch unadj peak sale po
tp reflect paid galapago transact partial off-set
risk-adjust npv
profit loss tax
cog revenu
 revenu
sg revenu
commerci headwind like well-understood consensu ahead
quarter gener believ eros legaci base busi
adequ consid consensu driven partli manag
effort manag expect expect may volatil
sensipar sale eros recent launch gener level
lesser extent neulasta still rel earli day expect see
sequenti progress biosimilar kanjinti amgevita well even
despit recent neg chmp opinion europ reduc
neulasta sensipar estim anticip continu gener eros
remov european contribut even model continu
believ pipelin drive growth offset base busi
eros novel oncolog biosimilar progress remain focu
lower tp reiter outperform rate
focu point call look detail biosimilar strategi
given recent announc launch mvasi kanjinti us
may discuss plan regard approv develop
releas half-lif extend version anti-bcma
may provid greater clariti could see updat
data expect substant updat on-going patent case
development regulatori market
valuat metric
number share
tp rate
intellectu properti clinic
price month
 close
inc biotechnolog compani engag
discoveri develop manufactur market human
price jul rate outperform target price analyst evan seigerman
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky scenario assum tvgr better
current assumpt base-busi greater
current forecast assum greater expect
growth biosimilar franchis slower expect
declin base busi also assum posit data
readout pipelin asset regulatori
approv abp kanjinti us abp abp
lower base busi sale poorer growth profil
biosimilar busi key pipelin asset assum
slower expect growth biosimilar franchis
regulatori headwind drug approv ip litig
scenario assum lose patent litig soliri
enbrel also assum neg data readout pipelin asset
charl martineau pm univers toronto figur amgen quarterli annual ep usd
cog revenu
 revenu
sg revenu
model updat given recent trend commentari modestli reduc
estim neulasta sensipar
remov even eu contribut ucb collabor profit light
chmp opinion modestli increas mvasi kanjinti us sale given
earlier launch forecast revenu revenu
ep ep
figur detail
stronger ingrezza perform expect season issu
medicar part coverag gap less factor continu believ
ingrezza outperform expect long-term cs vs factset
consensu howev project sale slightli ahead
expect vs factset consensu ahead
perform season plan switch medic recertif
dynam histor result lower sale neurocrin also expect
lower gross-to-net variat due medicar part coverag gap move
final payer dynam unlik limit out-performance
express script decis exclud ingrezza nation prefer
formulari unlik materi neurocrin state exclus impact
sale yet street overli focus exclus may
account lower expect compar project continu
believ ingrezza best-in-class treatment tardiv dyskinesia
drive revenu growth compani work increas penetr
reiter pt outperform rate
focu point call recent fda accept neurocrin nda
opicapon look detail surround potenti launch date
project launch neurocrin may also provid updat regard
gene therapi collabor voyag includ vy-aadc parkinson
diseas updat data readout timelin potenti fda requir trial
design furthermor look chang capit alloc prioriti
neurocrin previous state ingrezza main focu could see
greater interest collabor expand pipelin seen
valuat metric
number share
price month
 close
profit loss tax
cog revenu
 revenu
sg revenu
sale help drive
ahead ep revenu attract revenu
ep compar factset consensu averag
revenu cs vs current compani expect cf franchis
sale impli yoy growth histor vertex
conserv guidanceexclud project sale region without
formal reimburs agreement continu believ guidanc
conserv beatabl view cystic fibrosi cf revenu could
drive-fre cash flow vertex next compound-annual-growth-rate
estim includ risk-adjust sale uk franc increment
expect thesi predic non-cf revenu
pipelin gene therapi partnership interest although data still
earli continu believ littl valu reflect current
share price asset thu posit updat would surpris upsid
reiter tp outperform rate
focu point call call expect color tripl vx-
file time full data present also look greater uptak
symdeko germani drug launch recent expect
substanti updat reimburs uk franc could get
increment updat ou reimburs symkevi
partnership front would expect greater detail surround
deal expand crispr collabor add dmd
acquisit exon therapeut
valuat metric
number share
price month
 close
profit loss tax
cog revenu
 revenu
sg revenu
compani mention price
